Formidable Asset Management LLC Sells 3,813 Shares of Johnson & Johnson $JNJ

Key Points

• Formidable Asset Management cut its Johnson & Johnson stake by 16% in the third quarter, selling 3,813 shares. It retained 20,065 shares valued at about $5.1 million.
• Johnson & Johnson reported quarterly EPS of $2.59, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.4 billion. The company set 2026 EPS guidance of $11.05–$11.15.
• Recent company developments include FDA accelerated approval of RYBREVANT FASPRO for certain head and neck cancers, while a law firm announced an investigation into potential investor claims.

Formidable Asset Management LLC lowered its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 16.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 20,065 shares of the company's stock after selling 3,813 shares during the period. Johnson & Johnson comprises 0.7% of Formidable Asset Management LLC's holdings, making the stock its 25th largest position. Formidable Asset Management LLC's holdings in Johnson & Johnson were worth $5,096,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Verus Capital Partners LLC raised its stake in shares of Johnson & Johnson by 6.0% during the 3rd quarter. Verus Capital Partners LLC now owns 8,026 shares of the company's stock worth $2,125,000 after purchasing an additional 456 shares during the period. AlphaCentric Advisors LLC increased its holdings in Johnson & Johnson by 11.4% during the third quarter. AlphaCentric Advisors LLC now owns 1,549 shares of the company's stock worth $410,000 after buying an additional 158 shares during the last quarter. Tennessee Valley Asset Management Partners raised its position in Johnson & Johnson by 1.5% in the third quarter. Tennessee Valley Asset Management Partners now owns 3,211 shares of the company's stock worth $850,000 after acquiring an additional 48 shares during the period. Parallel Advisors LLC raised its position in Johnson & Johnson by 2.6% in the third quarter. Parallel Advisors LLC now owns 85,192 shares of the company's stock worth $22,554,000 after acquiring an additional 2,157 shares during the period. Finally, Prudent Man Investment Management Inc. boosted its stake in Johnson & Johnson by 68.3% in the third quarter. Prudent Man Investment Management Inc. now owns 589 shares of the company's stock valued at $156,000 after acquiring an additional 239 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $276.14 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The company has a market cap of $664.76 billion, a PE ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. Johnson & Johnson has a 52 week low of $185.12 and a 52 week high of $282.02. The firm's 50-day simple moving average is $265.91 and its two-hundred day simple moving average is $248.30.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company's revenue was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Research analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares in the company, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Weiss Ratings downgraded shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a research report on Friday, October 23rd. Scotiabank reaffirmed an "outperform" rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Erste Group Bank cut shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Wednesday, October 21st. Leerink Partners dropped their price objective on Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 14th. Finally, Wells Fargo & Company increased their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.